{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:45:51Z","timestamp":1773848751570,"version":"3.50.1"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA\/NV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.vaccine.2025.128015","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:08:32Z","timestamp":1765037312000},"page":"128015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world utilization and potential clinical and economic value of recombinant zoster vaccine and select preventive services recommended for older adults in the United States"],"prefix":"10.1016","volume":"71","author":[{"given":"Justin","family":"Gatwood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Gomez-Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikita","family":"Stempniewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.128015_bb0005","unstructured":"Lund P.S., Mukkamala S.B. Value of Preventive Services. https:\/\/www.ama-assn.org\/sites\/ama-assn.org\/files\/corp\/media-browser\/public\/about-ama\/councils\/Council%20Reports\/council-on-medical-service\/cms-csaph-joint-report-a17.pdf; 2017. [Accessed 5 July 2023]."},{"key":"10.1016\/j.vaccine.2025.128015_bb0015","unstructured":"United States Preventive Services Task Force. A & B Recommendations, https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation-topics\/uspstf-a-and-b-recommendations#:\u223c:text=A%20and%20B%20grade%20recommendations,moderate%20net%20benefit%20for%20patients.; 2023 [accessed March 18, 2024]."},{"key":"10.1016\/j.vaccine.2025.128015_bb0025","article-title":"Advisory committee on immunization practices centers for disease C, prevention. Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP)","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2025.128015_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.128015_bb0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the advisory committee on immunization practices - United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.128015_bb0040","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.vaccine.2018.11.056","article-title":"Cost-effectiveness of adult vaccinations: a systematic review","volume":"37","author":"Leidner","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128015_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2019.05.022","article-title":"A review of the cost-effectiveness of adult influenza vaccination and other preventive services","volume":"126","author":"Dabestani","year":"2019","journal-title":"Prev Med"},{"key":"10.1016\/j.vaccine.2025.128015_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7005a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2021-22 influenza season","volume":"70","author":"Grohskopf","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2025.128015_bb0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm6903a5","article-title":"Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the advisory committee on immunization practices - United States, 2019","volume":"69","author":"Havers","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.128015_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2025.128015_bb0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.128015_bb0075","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/ajt.16661","article-title":"Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the advisory committee on immunization practices-United States, 2022","volume":"22","author":"Weng","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.vaccine.2025.128015_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.mm7401a1","article-title":"Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged >\/=50 years: recommendations of the advisory committee on immunization practices - United States, 2024","volume":"74","author":"Kobayashi","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.128015_bb0085","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1001\/jama.2021.4417","article-title":"Screening for colorectal Cancer: updated evidence report and systematic review for the US preventive services task force","volume":"325","author":"Lin","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.128015_bb0090","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1001\/jama.2021.6238","article-title":"Screening for colorectal Cancer: US preventive services task force recommendation statement","volume":"325","author":"United States Preventive Services Task Force","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.128015_bb0095","unstructured":"Jatlaoui T.C., Hung M.-C., Srivastav A., Lu P.-J., Black C.L., Lindley M.C., et al. Vaccination Coverage among Adults in the United States, National Health Interview Survey, 2019\u20132020. https:\/\/www.cdc.gov\/adultvaxview\/publications-resources\/vaccination-coverage-adults-2019-2020.html; 2022. [Accessed 5 July 2023]."},{"key":"10.1016\/j.vaccine.2025.128015_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7003a1","article-title":"Surveillance of vaccination coverage among adult populations - United States, 2018","volume":"70","author":"Lu","year":"2021","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.vaccine.2025.128015_bb0105","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.ophtha.2021.04.017","article-title":"Effectiveness of the recombinant zoster vaccine for herpes zoster Ophthalmicus in the United States","volume":"128","author":"Lu","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.vaccine.2025.128015_bb0110","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128015_bb0120","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1080\/21645515.2020.1780847","article-title":"Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States","volume":"17","author":"Talbird","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.128015_bb0125","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1016\/j.vaccine.2021.07.029","article-title":"Cost-benefit analysis of vaccination against four preventable diseases in older adults: impact of an aging population","volume":"39","author":"Carrico","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128015_bb0130","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1016\/j.vaccine.2021.11.016","article-title":"Seasonal influenza vaccination is associated with reduced risk of death among Medicare beneficiaries(\u2606)","volume":"39","author":"Buchman","year":"2021","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2025.128015_bb0140","doi-asserted-by":"crossref","first-page":"A56","DOI":"10.1016\/j.vaccine.2021.01.016","article-title":"Estimating public health and economic benefits along 10 years of Fluzone(R) high dose in the United States","volume":"39","author":"Net","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128015_bb0145","doi-asserted-by":"crossref","first-page":"461","DOI":"10.15585\/mmwr.mm7013a1","article-title":"Use of selected recommended clinical preventive services - behavioral risk factor surveillance system, United States, 2018","volume":"70","author":"Song","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.128015_bb0150","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/infdis\/jiac088","article-title":"Assessing the cost-utility of universal hepatitis B vaccination among adults","volume":"226","author":"Hall","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128015_bb0155","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.vaccine.2018.03.030","article-title":"Hepatitis B vaccination coverage among adults aged\u00a0\u2265\u00a018\u00a0years traveling to a country of high or intermediate endemicity, United States, 2015","volume":"36","author":"Lu","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128015_bb0160","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1016\/j.vaccine.2022.10.002","article-title":"Factors associated with pneumococcal vaccine uptake among vulnerable older adults in the United States primary care setting","volume":"40","author":"Whaley","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128015_bb0165","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3233\/JAD-220361","article-title":"Risk of Alzheimer\u2019s disease following influenza vaccination: a claims-based cohort study using propensity score matching","volume":"88","author":"Bukhbinder","year":"2022","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.vaccine.2025.128015_bb0170","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/M18-2347","article-title":"A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations","volume":"170","author":"Prosser","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2025.128015_bb0175","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","article-title":"Cost-effectiveness of an Adjuvanted recombinant zoster vaccine in older adults in the United States","volume":"36","author":"Curran","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128015_bb0180","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/21645515.2018.1558689","article-title":"Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live","volume":"15","author":"Curran","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.128015_bb0185","first-page":"6;ofz219","article-title":"A cost-effectiveness analysis of an Adjuvanted subunit vaccine for the prevention of herpes zoster and post-herpetic neuralgia. Open forum","author":"Carpenter","year":"2019","journal-title":"Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128015_bb0190","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2060668","article-title":"Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults","volume":"18","author":"Janusz","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.128015_bb0195","first-page":"1567","article-title":"Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model","volume":"26","author":"Patterson","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.vaccine.2025.128015_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066312","article-title":"Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005-2011","volume":"8","author":"Kostova","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2025.128015_bb0205","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/cid\/ciz676","article-title":"Projected population benefit of increased effectiveness and coverage of influenza vaccination on influenza burden in the United States","volume":"70","author":"Hughes","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128015_bb0210","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.vaccine.2014.10.079","article-title":"Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors","volume":"33","author":"Chit","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128015_bb0215","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1473-3099(14)71087-4","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis","volume":"15","author":"Izurieta","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128015_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067260","article-title":"Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly","volume":"8","author":"McGarry","year":"2013","journal-title":"PloS One"},{"issue":"88\u201399","key":"10.1016\/j.vaccine.2025.128015_bb0225","first-page":"99a","article-title":"Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases","volume":"21","author":"Talbird","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.vaccine.2025.128015_bb0230","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.1016\/j.vaccine.2020.10.067","article-title":"Assessing the cost-utility of preferentially administering HEPLISAV-B vaccine to certain populations","volume":"38","author":"Rosenthal","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128015_bb0235","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jhm.2328","article-title":"Prior pneumococcal and influenza vaccinations and in-hospital outcomes for community-acquired pneumonia in elderly veterans","volume":"10","author":"Li","year":"2015","journal-title":"J Hosp Med"},{"key":"10.1016\/j.vaccine.2025.128015_bb0240","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/QAI.0000000000002916","article-title":"Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among adults with HIV-United States, 2008-2018","volume":"90","author":"Kobayashi","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2025.128015_bb0245","doi-asserted-by":"crossref","first-page":"S736","DOI":"10.1093\/ofid\/ofaa439.1651","article-title":"Epidemiology of invasive pneumococcal disease (IPD) following 18 years of pneumococcal conjugate vaccine (PCV) use in the United States [abstract 1470]","volume":"7","author":"Pilishvili","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128015_bb0250","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/cid\/ciy800","article-title":"Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization","volume":"68","author":"Pelton","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128015_bb0255","doi-asserted-by":"crossref","first-page":"6160","DOI":"10.1016\/j.vaccine.2017.09.050","article-title":"Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States","volume":"35","author":"Jacobs","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128015_bb0260","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12325-014-0115-y","article-title":"Cost-effectiveness of pneumococcal vaccines for adults in the United States","volume":"31","author":"Chen","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2025.128015_bb0265","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s11606-016-3651-0","article-title":"Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States","volume":"31","author":"Stoecker","year":"2016","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.vaccine.2025.128015_bb0270","unstructured":"Leidner A.J. Overview of three economic analyses of pneumococcal vaccinations at age 65. https:\/\/stacks.cdc.gov\/view\/cdc\/78093; 2019. [Accessed 5 July 2023]."},{"key":"10.1016\/j.vaccine.2025.128015_bb0275","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.ajkd.2019.01.025","article-title":"Cost-effectiveness of pneumococcal vaccination among patients with CKD in the United States","volume":"74","author":"Ishigami","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.vaccine.2025.128015_bb0280","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","article-title":"Cost-effectiveness of the Adjuvanted herpes zoster subunit vaccine in older adults","volume":"178","author":"Le","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2025.128015_bb0285","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1016\/j.jval.2022.04.096","article-title":"Impact of high-dose vs standard-dose influenza vaccine on respiratory hospitalizations among adults (abstract P75)","volume":"25","author":"Bianchini","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2025.128015_bb0290","first-page":"1","article-title":"Evaluating the relative vaccine effectiveness of Adjuvanted trivalent influenza vaccine compared to high-dose trivalent and other egg-based influenza vaccines among older adults in the US during the 2017-2018 influenza season","volume":"8","author":"Pelton","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.128015_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106066","article-title":"Tetanus, diphtheria and acellular pertussis (Tdap) vaccine for prevention of pertussis among adults aged 19 years and older in the United States: a cost-effectiveness analysis","volume":"134","author":"Cho","year":"2020","journal-title":"Prev Med"},{"key":"10.1016\/j.vaccine.2025.128015_bb0300","unstructured":"Centers for Disease Control and Prevention. BRFSS: Table of Colorectal Cancer Screening, https:\/\/chronicdata.cdc.gov\/Behavioral-Risk-Factors\/BRFSS-Table-of-Colorectal-Cancer-Screening\/evnt-bfr6; 2015 [accessed April 2023]."},{"key":"10.1016\/j.vaccine.2025.128015_bb0305","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/13696998.2020.1730123","article-title":"Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives","volume":"23","author":"Hathway","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.vaccine.2025.128015_bb0310","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/pop.2021.0185","article-title":"Cost-effectiveness of outreach strategies for stool-based colorectal Cancer screening in a Medicaid population","volume":"25","author":"Karlitz","year":"2022","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.vaccine.2025.128015_bb0315","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/03007995.2021.2015157","article-title":"Healthcare costs of colorectal cancer screening and events following colonoscopy among commercially insured average-risk adults in the United States","volume":"38","author":"Fisher","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.vaccine.2025.128015_bb0320","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10620-020-06541-7","article-title":"Impact of health insurance, poverty, and comorbidities on colorectal Cancer screening: insights from the medical expenditure panel survey","volume":"66","author":"Gawron","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.vaccine.2025.128015_bb0325","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamasurg.2013.8","article-title":"Impact of screening colonoscopy on outcomes in colon cancer surgery","volume":"148","author":"Amri","year":"2013","journal-title":"JAMA Surg"},{"key":"10.1016\/j.vaccine.2025.128015_bb0330","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.canep.2014.10.004","article-title":"Relative impact of earlier diagnosis and improved treatment on survival for colorectal cancer: a US database study among elderly","volume":"38","author":"Tong","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.vaccine.2025.128015_bb0335","doi-asserted-by":"crossref","first-page":"750","DOI":"10.7326\/M13-2263","article-title":"Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis","volume":"160","author":"van Hees","year":"2014","journal-title":"Ann Intern Med"},{"issue":"427\u2013439","key":"10.1016\/j.vaccine.2025.128015_bb0340","article-title":"Comparative effectiveness and cost effectiveness of a multitarget stool DNA test to screen for colorectal neoplasia","volume":"151","author":"Ladabaum","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.vaccine.2025.128015_bb0345","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/pop.2018.0008","article-title":"Balancing adherence and expense: the cost-effectiveness of two-sample vs one-sample fecal immunochemical test","volume":"22","author":"Smith","year":"2019","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.vaccine.2025.128015_bb0350","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2021.5746","article-title":"Colorectal Cancer screening: an updated modeling study for the US preventive services task force","volume":"325","author":"Knudsen","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.128015_bb0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244431","article-title":"Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model","volume":"15","author":"Piscitello","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2025.128015_bb0360","series-title":"Healthy people 2020 midcourse review. Hyattsville, MD","article-title":"Chapter 23: Immunization and infectious diseases","author":"National Center for Health Statistics","year":"2016"},{"key":"10.1016\/j.vaccine.2025.128015_bb0365","author":"Hung"},{"key":"10.1016\/j.vaccine.2025.128015_bb0370","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1016\/j.vaccine.2023.04.067","article-title":"Recombinant zoster vaccine coverage in the United States: an analysis of claims-based data","volume":"41","author":"Lewis","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128015_bb0375","author":"Stempniewicz"},{"key":"10.1016\/j.vaccine.2025.128015_bb0380","unstructured":"Centers for Disease Control and Prevention. How to Pay for Vaccines, https:\/\/www.cdc.gov\/vaccines-adults\/recommended-vaccines\/how-to-pay-adult-vaccines.html; 2024 [accessed November 15, 2024]."},{"key":"10.1016\/j.vaccine.2025.128015_bb0385","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2024.7348","article-title":"Shingles vaccination in Medicare part D after inflation reduction act elimination of cost sharing","volume":"331","author":"Qato","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.128015_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126537","article-title":"Herpes zoster vaccination among Medicare beneficiaries with and without prescription drug coverage","volume":"43","author":"Tsai","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128015_bb0395","unstructured":"Stoecker C. Economic assessment of PCV21 in U.S. Adults, https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-06-26-28\/02-Pneumococcal-Stoecker-508.pdf; 2024 [accessed Feb 28, 2025]."},{"key":"10.1016\/j.vaccine.2025.128015_bb0400","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/cid\/ciad355","article-title":"Burden of lower respiratory tract infections preventable by adult immunization with 15- and 20-valent pneumococcal conjugate vaccines in the United States","volume":"77","author":"Lewnard","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128015_bb0405","first-page":"143","article-title":"Vaccines for preventing influenza in healthy children, healthy adults, and older adults","volume":"100","author":"Cayley","year":"2019","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.vaccine.2025.128015_bb0410","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1016\/j.vaccine.2004.01.067","article-title":"Adolescent and adult pertussis vaccination: computer simulations of five new strategies","volume":"22","author":"Van Rie","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.128015_bb0415","author":"Leung"},{"key":"10.1016\/j.vaccine.2025.128015_bb0420","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.128015_bb0425","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Group ZOES. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.128015_bb0430","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/cid\/ciab629","article-title":"Zoster-049 study G. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70","volume":"74","author":"Boutry","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128015_bb0435","first-page":"9;ofac485","article-title":"Long-term protection against herpes zoster by the Adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open forum","author":"Strezova A, Diez-Domingo J, Al Shawafi K, Tinoco JC, Shi M, Pirrotta P, Mwakingwe-Omari A, Zoster-049 Study G","year":"2022","journal-title":"Infect Dis"},{"key":"10.1016\/j.vaccine.2025.128015_bb0440","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2025.128015_bb0445","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s41669-023-00438-7","article-title":"Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States","volume":"7","author":"Salem","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.vaccine.2025.128015_bb0450","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jval.2022.08.003","article-title":"Cost-effectiveness analysis of vaccination with recombinant zoster vaccine among hematopoietic cell transplant recipients and persons with other immunocompromising conditions aged 19 to 49 years","volume":"26","author":"Leidner","year":"2023","journal-title":"Value Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25013131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25013131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:01:05Z","timestamp":1773828065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25013131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":85,"alternative-id":["S0264410X25013131"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128015","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world utilization and potential clinical and economic value of recombinant zoster vaccine and select preventive services recommended for older adults in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.128015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 GSK Plc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128015"}}